Guggenheim Capital LLC lowered its position in shares of Zoetis Inc (NYSE:ZTS) by 9.6% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 88,886 shares of the company’s stock after selling 9,445 shares during the period. Guggenheim Capital LLC’s holdings in Zoetis were worth $10,462,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ZTS. Doyle Wealth Management lifted its position in Zoetis by 1.8% during the 4th quarter. Doyle Wealth Management now owns 4,322 shares of the company’s stock valued at $572,000 after acquiring an additional 77 shares during the period. Chilton Capital Management LLC grew its stake in shares of Zoetis by 4.1% in the first quarter. Chilton Capital Management LLC now owns 2,066 shares of the company’s stock worth $243,000 after acquiring an additional 81 shares during the period. Laurel Wealth Advisors LLC grew its stake in shares of Zoetis by 33.2% in the first quarter. Laurel Wealth Advisors LLC now owns 329 shares of the company’s stock worth $39,000 after acquiring an additional 82 shares during the period. Loomis Sayles & Co. L P grew its stake in shares of Zoetis by 9.5% in the fourth quarter. Loomis Sayles & Co. L P now owns 968 shares of the company’s stock worth $128,000 after acquiring an additional 84 shares during the period. Finally, Parkside Financial Bank & Trust grew its stake in shares of Zoetis by 6.3% in the first quarter. Parkside Financial Bank & Trust now owns 1,450 shares of the company’s stock worth $171,000 after acquiring an additional 86 shares during the period. 91.45% of the stock is owned by hedge funds and other institutional investors.

In other news, EVP Roman Trawicki sold 5,499 shares of the business’s stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $130.00, for a total value of $714,870.00. Following the transaction, the executive vice president now owns 8,340 shares of the company’s stock, valued at $1,084,200. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Heidi C. Chen sold 1,179 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $138.65, for a total transaction of $163,468.35. Following the completion of the sale, the executive vice president now owns 17,514 shares in the company, valued at approximately $2,428,316.10. The disclosure for this sale can be found here. Insiders sold 22,820 shares of company stock worth $2,992,087 in the last three months. Insiders own 0.17% of the company’s stock.

A number of analysts have recently commented on ZTS shares. Citigroup reduced their price target on shares of Zoetis from $139.00 to $131.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. UBS Group dropped their price objective on shares of Zoetis from $146.00 to $126.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Argus reissued a “buy” rating on shares of Zoetis in a report on Wednesday, June 3rd. Jefferies Financial Group began coverage on shares of Zoetis in a report on Wednesday, May 27th. They issued a “buy” rating and a $152.00 price objective on the stock. Finally, G.Research raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Tuesday, March 31st. Seven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $142.36.

NYSE:ZTS traded down $1.97 during trading hours on Friday, hitting $133.34. 19,836 shares of the stock traded hands, compared to its average volume of 1,770,995. The company has a quick ratio of 1.91, a current ratio of 2.77 and a debt-to-equity ratio of 2.22. Zoetis Inc has a 1 year low of $90.14 and a 1 year high of $146.26. The company has a market cap of $63.34 billion, a price-to-earnings ratio of 39.81, a price-to-earnings-growth ratio of 4.78 and a beta of 0.79. The stock has a 50 day moving average price of $133.69 and a 200 day moving average price of $130.85.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.86 by $0.09. Zoetis had a net margin of 25.41% and a return on equity of 67.72%. The business had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.50 billion. During the same quarter in the previous year, the firm earned $0.88 earnings per share. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. Equities analysts forecast that Zoetis Inc will post 3.33 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 17th will be issued a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 0.60%. The ex-dividend date of this dividend is Thursday, July 16th. Zoetis’s dividend payout ratio (DPR) is presently 21.98%.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Recommended Story: Oversold

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.